Table 3 Univariate Cox regression analysis of adverse factors of pancreatic carcinoma with progression-free survival and overall survival

Age (y)

 ≤ 60 (reference)

26

 > 60

71

2.39 (0.92–6.22)

0.07

2.63 (1.01–6.87)

0.048*

Gender

Female (reference)

39

Male

58

0.77 (0.39–1.55)

0.46

0.76 (0.38–1.51)

0.43

Race

White (reference)

70

African American

12

4.94 (2.02–12.10)

0.00*

5.51 (2.23–13.64)

0.00*

Other

6

2.27 (0.65–7.98)

0.20

2.14 (0.61–7.51)

0.23

Tumor stage

T1 (reference)

20

T2

53

0.77 (0.33–1.79)

0.58

0.75 (0.32–1.73)

0.49

T3

24

1.16 (0.45–2.94)

0.76

1.21 (0.47–3.07)

0.69

Tumor grading

G1

5

G2

67

0.66 (0.19–2.27)

0.51

0.67 (0.19–2.34)

0.54

G3

25

1.22 (0.33–4.48)

0.76

1.16 (0.32–4.24)

0.81

Lymph node involved

No (reference)

26

Yes

71

1.11 (0.51–2.41)

0.78

1.09 (0.50–2.35)

0.84

Duodenal invasion

Negative (reference)

44

Positive

53

0.47 (0.23–0.95)

0.03*

0.48 (0.23–0.97)

0.04*

Lymphovascular invasion

Negative (reference)

27

Positive

70

1.07 (0.49–2.32)

0.86

1.06 (0.48–2.28)

0.89

Perineural invasion

Negative (reference)

15

Positive

82

0.65 (0.26–1.59)

0.34

0.62 (0.25–1.53)

0.30

Ampullary invasion

Negative (reference)

63

Positive

34

0.96 (0.45–2.03)

0.91

0.91 (0.43–1.93)

0.82

CBD invasion

Negative (reference)

79

Positive

18

0.94 (0.36–2.45)

0.89

0.85(0.33–2.21)

0.74

Margin status

Negative (reference)

68

Positive

29

1.69 (0.81–3.57)

0.16

1.59 (0.76–3.33)

0.21